Physician profile
Ankur R Khosla
NPI 1861760985
$277,076.30
in general payments reported to CMS, 2019-2025
45 companies · $69K in 2025
The $69K reported for 2025 was more than what 99% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,938 · 2020: $15K · 2021: $32K · 2022: $65K · 2023: $51K · 2024: $38K · 2025: $69K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $36K · Consulting Fee: $34K · Royalty Or License: $31K · Honoraria: $20K · Travel and Lodging: $18K · Food and Beverage: $9,486 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $9,450 · Entertainment: $77.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $36,307.50 |
| Consulting Fee | $34,172.50 |
| Royalty Or License | $30,725.62 |
| Honoraria | $20,400.00 |
| Travel and Lodging | $17,505.99 |
| Food and Beverage | $9,485.89 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $9,450.00 |
| Entertainment | $77.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $78,998.09 | 2019-2025 | Proclaim, Eterna, Swift-Lock |
| Surgentec | $70,829.76 | 2021-2025 | Tilink, Ion, Ion Facet Screw System |
| Spinal Simplicity, LLC | $54,166.23 | 2020-2024 | Ha Minuteman G3-R |
| Averitas Pharma INC. | $30,509.96 | 2023-2025 | Qutenza |
| Boston Scientific Corporation | $19,067.30 | 2020-2025 | Axonics |
| Painteq LLC | $4,317.21 | 2021-2024 | Painteq |
| Grt US Holding, INC. | $2,584.02 | 2021-2022 | |
| Si-Bone, INC. | $2,253.66 | 2019-2023 | |
| Medtronic USA, INC. | $2,146.54 | 2019-2020 | |
| Nevro Corp. | $1,663.21 | 2019-2021 | |
| Relievant Medsystems, INC. | $1,437.12 | 2020-2023 | Intracept |
| Vertiflex, INC. | $1,301.15 | 2019 | |
| Vertos Medical, INC. | $1,227.62 | 2019-2024 | Mild Device Kit |
| Abbvie INC. | $1,072.12 | 2021-2025 | |
| Pacira Pharmaceuticals Incorporated | $841.05 | 2023-2025 | Iovera, Zilretta, Exparel |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,088,797.81 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ankur Khosla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.